Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-23T23:07:32.688Z Has data issue: false hasContentIssue false
  • English
  • Français

Varenicline-Induced Psychosis

Published online by Cambridge University Press:  07 November 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters
Information
CNS Spectrums , Volume 15 , Issue 7 , July 2010 , pp. 470 - 472
Copyright
Copyright © Cambridge University Press 2010

References

1. Champix: Prospektus ozeti. Available at: http//champix.com.tr. Accessed September 08, 2009.Google Scholar
2. FDA approves novel medication for smoking cessation. Available at: http//fda.gov/NewsEvents/NewsroomPressAnnouncements/2006/ucm108651.htm. Accessed September 08, 2009.Google Scholar
3.Kaur, K, Kaushal, S, Chopra, SC. Varenicline for smoking cessation: a review of the literature. Curr Ther Res Clin Exp. 2009;70:35–54.CrossRefGoogle ScholarPubMed
4.Ziedonis, D, Hitsman, B, Beckham, JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10(12):1691–1715.CrossRefGoogle ScholarPubMed
5.Cahill, K, Stead, LF, Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008;16(3):CD006103.CrossRefGoogle Scholar
6. Chantix (Varenicline) tablets. Important Safety Information. Available at: http//chatix.com/side-effects-safety-info.aspx. Accessed September 09, 2009.Google Scholar
7.Kintz, P, Evans, J, Villain, M, Cirimele, V. Smoking cessation with varenicline: a suicidal fatality. J Anal Toxicol. 2009;33:118–120.CrossRefGoogle ScholarPubMed
8.Stapleton, J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction. 2009;104(5):864–865.CrossRefGoogle ScholarPubMed
9.Kohen, I, Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder [letter]. Am J Psychiatry. 2007;164:1269–1270.CrossRefGoogle Scholar
10.Popkin, MK. Exacerbation of recurrent depression as a result of treatment with varenicline [letter]. Am J Psychiatry. 2008;165:6.CrossRefGoogle ScholarPubMed
11.Lyon, G J. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission [letter]. J Clin Psychopharmacol. 2008;28(6):720–721.CrossRefGoogle Scholar
12.Morstad, AE, Kutscher, EC. Hypomania with agitation associated with varenicline use in bipolar II disorder [letter]. Ann Pharmacother. 2008;42:288.CrossRefGoogle ScholarPubMed
13.Liu, ME, Tsai, SJ, Yang, ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizoaffective disorder [letter]. CNS Spectr. 2009;14(7):346.CrossRefGoogle Scholar
14.Alhatem, F, Black, JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharm. 2009;32:117–118.CrossRefGoogle Scholar
15.Freedman, R. Exacerbation of schizophrenia by varenicline [letter]. Am J Psychiatry. 2007;164:1269.CrossRefGoogle ScholarPubMed
16.Pumariega, AJ, Nelson, R, Rotenberg, L. Varenicline induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13(6):511–514.CrossRefGoogle Scholar
17.Food and Drug Administration. Important Information on Chantix ( Varenicline). Available at: http://www.fda.gov/Drugs/Drugsafety/PublicHealthAdvisories/UCM051136. Accessed September 08, 2009.Google Scholar
18.Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.CrossRefGoogle ScholarPubMed
19.Fatemi, SH. Varenicline efficacy and tolerability in a subject with schizophrenia [letter]. Schizophr Res. 2008;103:328–329.CrossRefGoogle Scholar
20.Evins, AE, Goff, DC. Varenicline treatment for smokers with schizophrenia: a case series [letter]. J Clin Psychiatry. 2008;69(6):1016.CrossRefGoogle ScholarPubMed
21.Ochoa, E. Varenicline reduced smoking behaviour in a mentally ill person [letter]. J Psychopharmacol. 2009;23(3):340–341.CrossRefGoogle Scholar
22.Stapleton, JA, Watson, L, Spirling, LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2007;103:146–154.CrossRefGoogle Scholar
23.Smith, RC, Lindenmayer, JP, Davis, JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009; 110: 149–155.CrossRefGoogle ScholarPubMed
24.Patterson, F, Jepson, C, Strasser, AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009; 65(2): 144–149.CrossRefGoogle ScholarPubMed
25.Hughes, JR, Higgins, ST, Bickel, WK. Nicotine withdrawal versus other withdrawal syndromes: similarities and dissimilarities. Addiction. 1994; 89: 1461–1470.CrossRefGoogle ScholarPubMed
26.Hughes, RH. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008; 98: 169–178.CrossRefGoogle ScholarPubMed